Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	4.20B +26.1%
Revenue (ttm)	392.83M +5.2%
Net Income	26.30M +49.7%
EPS	0.10 +54.1%
Shares Out	265.16M
PE Ratio	160.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,253,005
Average Volume	5,266,400
Open	15.85
Previous Close	14.97
Day's Range	14.85 - 15.97
52-Week Range	10.17 - 19.98
Beta	0.33
RSI	52.09
Earnings Date	Mar 26, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 530
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2024, Guanhao Biotech's revenue was 377.48 million, a decrease of -6.60% compared to the previous year's 404.18 million. Earnings were 27.42 million, a decrease of -11.57%.